---
schema_version: "secwatch.filing_event.v1"
accession: "0001625297-26-000028"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2026-09-15T20:28:36+00:00"
generated_at: "2026-09-15T20:29:08.327307+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Indivior accelerates RB copacker supply deal termination to Jan 15, 2027

## Summary
- Indivior UK and Reckitt Benckiser Healthcare UK terminated Copacker Supply Agreement effective Jan 15, 2027, vs original Dec 31, 2027.
- RB to manufacture additional volumes of SUBOXONE/SUBUTEX tablets before termination; Indivior identified a new supplier.
- Indivior to pay RB costs (under absorption, asset disposal, redundancy, incentive) that are fixed/capped and stated as not material.
- New supplier agreement not expected to be material and enforceable only after validation of manufacturing process.

## SEC filing metadata
- accession: 0001625297-26-000028
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2026-09-15T20:28:36+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000162529726000028/0001625297-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000162529726000028/indv-20260909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001625297-26-000028
- JSON: https://secwatch.observer/filing/0001625297-26-000028.json
- Plain text: https://secwatch.observer/filing/0001625297-26-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.